Panacea Capital

Panacea Capital is a global life sciences investment firm that specializes in incubating and scaling innovative healthcare and biotechnology companies. Formerly known as Panacea Venture, the firm operates with an asset-centric approach, often leading the formation of new biopharmaceutical entities to advance clinically validated drug candidates. With a presence across the U.S. and Asia, Panacea Capital leverages deep expertise in drug development and cross-border execution to accelerate the path from discovery to commercialization. The firm's portfolio spans diverse therapeutic areas, including cardiovascular medicine, oncology, and regenerative medicine, featuring high-conviction assets like the Phase 3-ready heart failure treatment istaroxime. Through its venture building model, Panacea Capital actively manages the development of its portfolio companies to address significant unmet medical needs globally.